Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

Artrya’s Growth Outlook Faces Pressure from Ongoing Losses

Sep 20, 2026 | Team Kalkine
Artrya’s Growth Outlook Faces Pressure from Ongoing Losses
Image source: shutterstock

  • AYA:ASX
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (AU$)

This report is an updated version of the report published on 21 September 2026 at 11:43 AM AEST.

Artrya Limited (ASX: AYA)

Artrya Limited (ASX: AYA) is an Australian medical-technology firm developing AI-powered software to detect, diagnose and manage coronary artery disease. Its flagship product, “Salix”, uses deep learning to analyse coronary CT angiography scans, helping physicians identify plaque, assess risk and streamline workflow.


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…